In the News
SHRM | 25.05.2026
Preparing Organisations for AI-Led Workforce Transformation
Campaign India | 24.04.2026
When we go wrong, we are bold enough to sunset brands: Sai Ponugoti
Campaign India | 23.04.2026
How Lacto Calamine Revitalized Its Identity After 50 Years in India
PMPS Magazine | 23.04.2026
Tablet-in-capsule technology: bridging paediatric and adult dosing requirements
Express Pharma | 06.04.2026
Leading people in the age of AI
Express Pharma | 03.04.2026
Patent expiries ahead, is India Pharma Inc ready?
Investment Report by Washington Post | 23.03.2026
Exclusive interview of Peter DeYoung
Chemistry Today | 16.03.2026
Panel discussion on Quality, Supply Chain Security & Agility in Pharma
BW People | 08.03.2026
When Women Thrive, We All Rise
Outlook Business | 05.03.2026
US Biotech Funding, Rising M&A Signal Gradual CDMO Revival: Nandini Piramal
Financial Express | 02.03.2026
‘Taking a structured approach to AI scaling’: Viral Gandhi, President & Group CIO, Piramal Group
ET Pharma | 17.02.2026
Pharma’s risk appetite gains regulatory traction - bridging specialisation key to crack the global code
HRO Today | 05.02.2026
How Story-First HR Can Transform Gen Z Engagement at Work
Express Pharma | 04.02.2026
Friendshoring: Pharma’s next supply chain bet?
The Hindu Business Line | 20.12.2025
Piramal Consumer aims to scale up revenues to $200 m by FY30
CNBC TV18 | 12.12.2025
India's CDMO Industry Is Significantly Smaller Than China: Piramal Pharma
People Matters | 08.12.2025
Skilling the next pharma workforce: From compliance training to capability creation
Manufacturing Chemist | 26.11.2025
Manufacturing Chemist Stand Side with Piramal Pharma Solutions
Pharma Source | 26.11.2025
How Piramal Pharma Built a $1 Billion CDMO by Solving Client Problems, Not Selling Services
The Economic Times | 24.11.2025
Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma
Financial Times | 11.11.2025
My Mantra
Mint | 07.11.2025
Piramal bets on US biopharma rebound
The Hindu Business | 07.11.2025
Piramal PharmasQ2 numbers hit by CDMO destocking
ET NOW | 17.10.2025
ET NOW’s Best Organisations for Women 2025
ContractPharma | 08.10.2025
From Orphan Drugs to Advanced Therapies- Piramal's Global R&D Perspective
ExpressPharma | 18.09.2025
From Compliance to Commitment: How Piramal Pharma is Reimagining Sustainability in Pharma
Exchange4Media | 27.08.2025
Balancing traditional media with digital & influencers to speak to speak to the many Indias
ET HRWorld | 25.08.2025
Rethinking leadership: From few at the top to many across the floor
Pharma Manufacturing | 16.07.2025
Piramal Pharma to expand two US facilities, target hot ADC and fill-finish markets
Financial Express | 15.07.2025
Piramal Pharma’s Project Catalyst, NxGen, to increase profitability to 3X: Viral Gandhi, Group CIO
PharmTech | 30.05.2025
From Discovery to Delivery: How 17³Ô¹ÏÍø is Strengthening its Drug Development Capabilities
The Economic Times | 25.05.2025
China’s India headache: The growing pharmaceutical industry
Pharma Bio World | 27.05.2025
Interview in Pharma Bio World: We aim to grow our CDMO revenues to USD 1.2 billion by FY2030
The Economic Times | 17.05.2025
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Moneycontrol | 16.05.2025
Piramal Pharma’s Nandini Piramal eyes FY30 milestone amid muted FY26 outlook
Mint | 15.05.2025
Piramal Pharma to see muted CDMO growth on US jitters; strong recovery in FY27
Business Standard | 15.05.2025
Piramal Pharma expects single-digit growth in FY26 amid uncertainties
The Hindu Business Line | 15.05.2025
Global drugmakers ‘prolonged decision-making’ casts shadow on CDMOs: Nandini Piramal
PMPS | 24.04.2025
Tablet-in capsule formulations: enhancing patient compliance and therapeutic outcomes
Fortune India | 14.04.2025
Pharma's progress
Entrepreneur India | 12.04.2025
The Ceiling Breaker: Nandini Piramal, Chairperson, 17³Ô¹ÏÍø (PPL)
Mint | 31.03.2025
The Piramal Success Formula: Consensus for Father, Data for Daughter
Business World | 29.03.2025
Her Motto: Doing Well, Doing Good
Onyx | 24.03.2025
How Piramal Pharma plans to become a multi-billion dollar business
Fortune India | 18.03.2025
Nandini Piramal charts bold growth path: Piramal Pharma eyes $2 Billion Revenue by FY30
Outlook | 10.03.2025
Shaping the Future
Express Pharma | 12.02.2025
Pharma’s strategic path to growth in the nutra maze
Mint | 30.01.2025
Piramal Pharma to expand injectables portfolio in complex hospital generics business
Business Standard | 30.01.2025
Piramal Pharma aim to double CDMO revenues to $1.2 bn by FY30: Nandini Piramal
The Hindu Business Line | 30.01.2025
Piramal Pharma looks to next few months with cautious optimism
Molecule to Market | 17.01.2025
Peter DeYoung, CEO, Piramal Global Pharma on outsourcing space of the global drug development sector
Business Standard | 18.12.2024
Booster dose for Piramal Pharma on growth hopes
The Economic Times | 17.12.2024
Piramal Pharma shares zoom 8% as JM Financial sets Rs 340 target
Mint | 17.12.2024
Piramal Pharma share price jumps 4.5% after JM Financial issues ’buy’ rating, sees 36% upside
Business Standard | 17.12.2024
Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed
The Medicine Maker | 27.11.2024
Navigating Market Changes: Piramal Pharma’s Growth and Key Industry Trends
Business Today | 24.11.2024
Building Agility and Resilience
Mint | 21.11.2024
Piramal unfazed even as Trump return may fuel uncertainty in its biggest market
PTI | 27.10.2024
Piramal Pharma deploying USD 85 mn capex this fiscal: Nandini Piramal
Citeline | 18.10.2024
Nandini Piramal on PPL’s growth with Citeline
Bioprocess International | 18.10.2024
Piramal announces $80m expansion to injectable manufacturing facility
Bloomberg | 04.10.2024
India’s Piramal Pharma Aims to Double Revenue in Five Years.
Moneycontrol | 04.10.2024
Piramal Pharma aims to double revenue in five years
Pharma Horizon - Biologics | 30.09.2024
Rashida Najmi on Anti-body Drug Conjugates (ADCs) in Pharma Horizon – Biologics report.
PTI | 25.09.2024
Piramal Pharma aims to be over USD 2bn entity by FY30: Chairperson Nandini Piramal
The Economic Times | 25.09.2024
Piramal Pharma targets to double revenue in 5 years
The Times of India | 25.09.2024
Piramal Pharma aims to double turnover to $2 billion by 2030
Bloomberg | 25.09.2024
US Firms Reaching Out as Biosecure Act Closes in, Piramal Says
Business Standard | 25.09.2024
Pharmaceutical firm Piramal Pharma eyes to double revenue to $ 2 bn by FY30
The Hindu Business Line | 25.09.2024
Piramal Pharma aims to be a $2 billion company by 2030
CNBC TV18 | 25.09.2024
Nandini Piramal details 5-year growth strategy, expects strong profit growth this year
ET Now | 25.09.2024
Piramal Pharma Targets $2 Bn Revenue By 2030 | Focus On Organic Growth & Innovation
Mint | 25.09.2024
Piramal Pharma share price rises 8%: 3 key reasons why Jefferies expects more gains
Business Standard | 25.09.2024
Piramal Pharma soars 9% as co targets 2x revenue, 3x Ebitda margin by FY30
Moneycontrol | 25.09.2024
Buy Piramal Pharma; target of Rs 260: Motilal Oswal
Moneycontrol | 25.09.2024
Piramal Pharma gains 8% as co aims for $2 billion revenue by 2030, Jefferies ups price target
Business Today | 25.09.2024
Piramal Pharma shares jump 9% on growth plans; brokerages see more upside potential
NDTV Profit | 25.09.2024
Piramal Pharma Shares Jump As Jefferies Hikes Target Price
CNBC TV18 | 25.09.2024
Piramal Pharma wants to be a $2 billion global firm by 2030, analysts give 5-year plan a thumbs up
indiatimes.com | 22.07.2024
Budget 2024 : Experts advocate for boosting investment, incentivised schemes, and preventive healthcare, ET HealthWorld (indiatimes.com)
ET Now | 22.07.2024
ET NOW’s Best Organizations for Women in India Book
Business Standard | 20.07.2024
US Biosecure Act may boost Indian CDMO, CRO firms
Business Standard | 19.07.2024
US Biosecure Act may boost Indian CDMO, CRO firms
The Economic Times | 14.05.2024
In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
The Economic Times | 14.05.2024
In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal
Mint | 14.05.2024
Piramal to focus on brownfield expansion, cut debt before acquisitions
The Hindu Business Line | 13.05.2024
On-patent and differentiated offerings will give Piramal Pharma an edge, says Chairperson
CNBC TV18 | 13.05.2024
Piramal Pharma aims to grow innovation business faster than generics
Business Standard | 13.05.2024
Piramal Pharma open to partnerships in OTC; eyes further debt reduction
Business Standard | 11.05.2024
Piramal Pharma Q4 profit Jumps 102% to Rs 101.3 cr, FY24 revenue Up 18%
CNBC TV18 | 10.05.2024
Piramal Pharma Q4 net profit zooms to ₹101 crore, decalres dividend
Deccan Herald | 01.03.2024
Piramal Pharma eyes 15% revenue uptick propelled by CDMO biz
CNBC TV18 | 23.02.2024
Piramal Pharma: The Road To Recovery
Livemint | 01.02.2024
Piramal Pharma Q3 FY24 results : profit at ₹10.11Cr, Revenue increased by 14.14% YoY
Business Today | 24.12.2023
MPW 2023: For Piramal Pharma Chairperson Nandini Piramal sustainability is synonymous with growth
Business Today | 11.12.2023
BT MPW 2023: Nandini Piramal says not all companies maintain high standards in Indian pharma
Business Today | 09.12.2023
Infosys founders are an inspiration': Ajay Piramal's daughter and Piramal Pharma chief looks at Nandan Nilekani as an idol
Business Today | 08.12.2023
#BTMPW 2023: A Path Of Leadership And Innovative Brilliance
Business Today | 04.12.2023
Piramal Pharma allocates Rs 330 crore towards capex H2FY24
Pharma Boardroom | 30.11.2023
Peter DeYoung – CEO, Global Pharma, 17³Ô¹ÏÍø
Times of India | 18.11.2023
Piramal Pharma focuses on organic growth, cost check
The Financial Express | 08.11.2023
We will focus on revenue growth, cost optimisation, and debt reduction: Nandini Piramal, Chairperson, Piramal Pharma
Business Standard | 07.11.2023
Should touch Rs 1K crore from OTC this year, says Nandini Piramal
The Hindu BusinessLine | 06.11.2023
Recovery and turnaround this year - Piramal Pharma Chairperson
Mint | 28.10.2023
Piramal Pharma revenue up 11% to ₹1,911 crore in Q2
CNBC-TV18 | 28.09.2023
Piramal Pharma's US manufacturing unit successfully completes USFDA inspection
Money Control | 27.09.2023
Piramal Pharma up almost 4% on green signal from US FDA for Bethlehem plant
Pharm Tech | 13.09.2023
Interview with Piramal’s Peter DeYoung at DCAT
Business Standard | 08.09.2023
Piramal Pharma is aiming to achieve zero waste to landfill by FY25
BW Legal World | 06.09.2023
Sebi Disposes Of Proceeding Against Piramal Pharma
The Economic Times | 30.08.2023
REC, Zee and NCC among stocks with up to 25% upside
Capital Market | 22.08.2023
Piramal Pharma allots 12.96 cr equity shares on rights basis
Adgully | 11.08.2023
Piramal Consumer Healthcare introduces i-activ menstrual cups in their active range
Mint | 08.08.2023
Piramal Pharma rights issue opens today. Price, ratio, other details in five points
The Economic Times | 04.08.2023
Piramal Pharma posts net loss of Rs 99 crore in Q1FY24
CNBC TV18 | 02.08.2023
Piramal Pharma Rights Issue: Record date today, here's all you need to know
The Economic Times | 01.08.2023
Pickup in contract manufacturing biz set to drive growth: Piramal Pharma
Moneycontrol | 28.07.2023
Piramal Pharma rights issue at Rs 81 a share, opens August 8
The Economic Times | 18.07.2023
Piramal Pharma's Rs 1,050-cr rights issue gets Sebi's nod
Passionate Marketing | 28.06.2023
Piramal Consumer Healthcare expands the Tetmosol soap brand; introduces the Icy Cool variant
Business Standard | 06.06.2023
Piramal Critical Care appoints US-based Jeffrey Hampton as President, COO
The Economic Times | 26.05.2023
Piramal Pharma may double in a year; 4 metal stocks can give 20% return in 3 months : Sanjiv Bhasin
Mint | 25.05.2023
Earnings Impact: Piramal Pharma soars 13% as company turns profitable in March quarter
Pharmtech | 09.05.2023
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions
The Economic Times | 09.05.2023
IPL-flavoured portfolio: Smallcase manager Divam Sharma reveals his playing XI stocks
CNBC-TV18 | 18.04.2023
US FDA completes inspection at Piramal Pharma Sellersville manufacturing unit
The Economic Times | 11.04.2023
Hyderabad emerging as life sciences hub, with global and domestic pharmaceutical firms
The Hindu Business Line | 06.04.2023
Piramal Pharma Rights issue: Negatives priced in
Moneycontrol | 03.04.2023
Piramal Pharma zooms 5% on zero observations from US FDA
Free Press Journal | 01.04.2023
US FDA conducts GMP inspection at Piramal Pharma's Digwal facility
Business Today | 06.03.2023
MPW 2022: How Nandini Piramal is growing Piramal Pharma
The Hindu Business Line | 24.02.2023
Access to capital, regulatory reforms key to boost innovation in pharma industry: CEOs
ET Healthworld | 26.02.2023
Top Pharma CEOs optimistic about future growth opportunities, foresee the rise of India on global stage
Outsourcing Pharma | 21.02.2023
Piramal begins production at API facility in Michigan
Business Standard | 16.02.2023
Piramal Pharma gains after US facility gets EIR
The Economic Times | 09.02.2023
Piramal Pharma Q3 Results: Firm reports Rs 90 cr loss, gets board nod to raise up to Rs 1,050 cr
Medical Buyer | 09.02.2023
Piramal pharma shared down 10% on weak operational performance
Business Today | 17.01.2023
Piramal Pharma is emerging as a new pharma giant; what's driving the company's growth?
CNBC-TV18 | 14.01.2023
USFDA issues Form-483 with two observations to Piramal Pharma's Sellersville unit
The Economic Times | 11.01.2023
Carlyle buys wellness & beauty co VLCC, pays $275-$300 mn for nearly 70% stake
The Hindu Business Line | 09.01.2023
Pharma’s deal street. Managing bottomlines without losing sight of patient needs
The Economic Times | 19.12.2022
Piramal Pharma expects healthy growth in its key businesses. But does it cure the debt ailment?
Business Standard | 09.11.2022
Piramal Pharma posts Q2 net loss of Rs 37 cr, revenue grows to Rs 1,720 cr
Business Standard | 27.10.2022
MSCI sets aside Piramal Pharma's exclusion from global standard index
Indiainfoline | 25.10.2022
Piramal Pharma to invest Rs1,200 in UK over the next 12 to 18 months
The Economic Times | 25.10.2022
Piramal Pharma to inject funds into expansion, acquisitions
India Education Diary | 20.10.2022
Piramal Pharma Introduces Nixit, Its Smoking Cessation Brand With A New Campaign #QuititwithNixit In Karnataka
The Indian Express | 20.10.2022
Piramal Pharma falls 4.98 pc after listing
Financial Express | 20.10.2022
Piramal Pharma earmarks Rs 1,200 cr capex over next 24 months: Nandini
Mint | 20.10.2022
‘Our plan will allow us to grow 15% annually over 3-5 years’
The Economic Times | 20.10.2022
Piramal Pharma gets locked in lower circuit
CNBC TV18 | 20.10.2022
Indian pharma industry is ‘recession proof’: Piramal Chairman
India Education Diary | 20.10.2022
Piramal Pharma Introduces Nixit, Its Smoking Cessation Brand With A New Campaign #QuititwithNixit In Karnataka
Mint | 19.10.2022
Piramal Pharma shares list on stock exchanges after demerger
Business Standard | 19.10.2022
We won't make an acquisition just because we have to: Piramal Pharma chief
The Economic Times | 19.10.2022
Piramal Pharma shares hit 5% lower circuit after listing
Business Standard | 19.10.2022
Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close
India Today | 19.10.2022
Yapan Bio Adds New Process Development Facility; Expands Capacity and Capabilities in Large Molecule Therapeutics
Moneycontrol | 17.10.2022
Piramal Pharma to list shares on October 19
The Economic Times | 17.10.2022
Piramal Pharma to debut on bourses on Wednesday
ET Healthworld | 10.10.2022
Piramal Pharma unveils its Sustainability Report FY21–22
Market Screener | 29.09.2022
Piramal Enterprises : Pharma Appoints Vibha Paul Rishi as Non- Executive Director to its Board of Directors
BW Disrupt | 22.09.2022
Piramal Pharma's Consumer Division Introduces D2C Platform Wellify
The Economic Times | 13.09.2022
Piramal Pharma in Talks for $225m Offshore Loans
Refine your search